nach oben

Quality of Life Research

Erschienen in:

01.10.2009

Health utility scores of colorectal cancer based on societal preference in Japan

verfasst von: Takeru Shiroiwa, Takashi Fukuda, Kiichiro Tsutani

Erschienen in: Quality of Life Research | Ausgabe 8/2009

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Purpose

We measured health utility scores of colorectal cancer (CRC) patients from a societal perspective in Japan.

Methods

Twenty-five states of health were described: four metastatic states without severe adverse events (AEs), 16 metastatic states with Grade 3/4 AEs, four adjuvant states, and one terminal state. A total of 1,500 respondents stratified by age and gender were recruited randomly from the largest Web-panel in Japan. Respondents were allocated randomly to three of the 25 health states and answered questionnaires by standard gamble (SG) and time trade-off (TTO) methods.

Results

Although utility scores of metastatic CRC receiving XELOX (capecitabine plus oxaliplatin) chemotherapy were 0.48(SG and TTO) (with stoma) and 0.57(SG) or 0.59(TTO) (without stoma), utility scores of those receiving FOLFOX4 (5-fluorouracil/folinic acid and oxaliplatin) chemotherapy were 0.42(SG) or 0.43(TTO) (with stoma) and 0.52(SG) or 0.53(TTO) (without stoma). These differences between XELOX and FOLFOX4 were statistically significant (P = 0.0198 in SG and P = 0.0059 in TTO). Stage 3/4 AEs decreased utility scores to 0.35–0.4 and 0.4–0.45 in the presence and absence of stoma, respectively.

Conclusions

XELOX was generally considered a significantly preferable chemotherapy regimen compared to FOLFOX4 for CRC in Japan. Almost all Grade 3/4 AEs and stoma significantly decreased utility scores. These differences are dependent on the accuracy of the health state description and to confirm these results. In future research, it would be preferable that preference-based HRQoL measures are used directly in patients if utility scores are practically measurable by such method.

Vorheriger Artikel Using cognitive interviews to evaluate items for measuring sexual functioning across cancer populations: improvements and remaining challenges

Nächster Artikel Developing a descriptive system for a new preference-based measure of health-related quality of life for children

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Ministry of Health, Labor and Welfare. (2007). Population Survey Report [in Japanese].

Center for Cancer Control and Information Services, National Cancer Center, Japan. (2007). Regional Cancer Records and Estimated National Figures [in Japanese].

Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., et al. (2000). Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-analysis group in cancer. Lancet, 356(9227), 373–378.PubMedCrossRef

Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. New England Journal of Medicine, 343(13), 905–914.PubMedCrossRef

Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 355(9209), 1041–1047.PubMedCrossRef

Tournigand, C., Andre, T., Achille, E., Lledo, G., Flesh, M., et al. (2004). FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. Journal of Clinical Oncology, 22(2), 229–237.PubMedCrossRef

de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology, 18(16), 2938–2947.PubMed

Porschen, R., Arkenau, H. T., Kubicka, S., Greil, R., Seufferlein, T., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group. Journal of Clinical Oncology, 25(27), 4217–4223.PubMedCrossRef

Diaz-Rubio, E., Tabernero, J., Gomez-Espana, A., Massuti, B., Sastre, J., et al. (2007). Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish cooperative group for the treatment of digestive tumors trial. Journal of Clinical Oncology, 25(27), 4224–4230.PubMedCrossRef

10.

Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., et al. (2008). Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology, 26(12), 2006–2012.PubMedCrossRef

11.

Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., et al. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. Journal of Clinical Oncology, 26(12), 2013–2019.PubMedCrossRef

12.

Rothenberg, M. L., Cox, J. V., Butts, C., Navarro, M., Bang, Y. J., et al. (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study. Annals of Oncology, 19(10), 1720–1726.PubMedCrossRef

13.

Tsuchiya, A., Ikeda, S., Ikegami, N., Nishimura, S., Sakai, I., et al. (2002). Estimating an EQ-5D population value set: The case of Japan. Health Economics, 11(4), 341–353.PubMedCrossRef

14.

Torrance, G. W., Furlong, W., Feeny, D., & Boyle, M. (1995). Multi-attribute preference functions. Health utilities index. Pharmacoeconomics, 7(6), 503–520.PubMedCrossRef

15.

The EuroQol Group. (1990). EuroQol—a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.CrossRef

16.

Brazier, J., Usherwood, T., Harper, R., & Thomas, K. (1998). Deriving a preference-based single index from the UK SF-36 Health Survey. Journal of Clinical Epidemiology, 51(11), 1115–1128.PubMedCrossRef

17.

Brazier, J., Roberts, J., & Deverill, M. (2002). The estimation of a preference-based measure of health from the SF-36. Journal of Health Economics, 21(2), 271–292.PubMedCrossRef

18.

Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.PubMed

19.

Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.PubMedCrossRef

20.

Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal. Journal of Health Economics, 5(1), 1–30.PubMedCrossRef

21.

Lloyd, A., Nafees, B., Narewska, J., Dewilde, S., & Watkins, J. (2006). Health state utilities for metastatic breast cancer. British Journal of Cancer, 95(6), 683–690.PubMedCrossRef

22.

Milne, R. J., Heaton-Brown, K. H., Hansen, P., Thomas, D., Harvey, V., et al. (2006). Quality-of-life valuations of advanced breast cancer by New Zealand women. Pharmacoeconomics, 24(3), 281–292.PubMedCrossRef

23.

Lidgren, M., Wilking, N., Jonsson, B., & Rehnberg, C. (2007). Health related quality of life in different states of breast cancer. Quality of Life Research, 16(6), 1073–1081.PubMedCrossRef

24.

Stewart, S. T., Lenert, L., Bhatnagar, V., & Kaplan, R. M. (2005). Utilities for prostate cancer health states in men aged 60 and older. Medical Care, 43(4), 347–355.PubMedCrossRef

25.

Doyle, S., Lloyd, A., & Walker, M. (2008). Health state utility scores in advanced non-small cell lung cancer. Lung Cancer, 62(3), 374–380.PubMedCrossRef

26.

Nafees, B., Stafford, M., Gavriel, S., Bhalla, S., & Watkins, J. (2008). Health state utilities for non small cell lung cancer. Health and Quality of Life Outcomes, 6, 84.PubMedCrossRef

27.

Gold, M., Siegel, J., Russell, L., & Weinstein, M. (1996). Cost-effectiveness in health and medicine. Oxford: Oxford University Press.

28.

Ministry of Education, Culture, Sports, Science and Technology. (2008). Labor force survey [in Japanese].

29.

Ramsey, S. D., Andersen, M. R., Etzioni, R., Moinpour, C., Peacock, S., et al. (2000). Quality of life in survivors of colorectal carcinoma. Cancer, 88(6), 1294–1303.PubMedCrossRef

30.

Wilson, T. R., Alexander, D. J., & Kind, P. (2006). Measurement of health-related quality of life in the early follow-up of colon and rectal cancer. Diseases of the Colon and Rectum, 49(11), 1692–1702.PubMedCrossRef

31.

Ko, C. Y., Maggard, M., & Livingston, E. H. (2003). Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: A nationwide, population-based assessment. Journal of Surgical Research, 114(1), 1–5.PubMedCrossRef

Titel: Health utility scores of colorectal cancer based on societal preference in Japan
verfasst von: Takeru Shiroiwa
Takashi Fukuda
Kiichiro Tsutani
Publikationsdatum: 01.10.2009
Verlag: Springer Netherlands
Erschienen in: Quality of Life Research / Ausgabe 8/2009
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-009-9513-z

Springer Professional

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 8/2009

Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE™ (cancer of the prostate strategic urologic research endeavor) database

Responsiveness of the Harris Hip Score and the SF-36: five years after total hip arthroplasty

Developing a descriptive system for a new preference-based measure of health-related quality of life for children

Negative and positive affect are independently associated with patient-reported health status following percutaneous coronary intervention

Sampling in population-based cancer caregivers research

Impact of mental disorders and chronic physical conditions in health-related quality of life among primary care patients: results from an epidemiological study

Premium Partner